NCT00002921

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: SWOG Cancer Research Network · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.

Detailed description

OBJECTIVES: I. Assess the response of patients with adrenocortical carcinoma treated with suramin. II. Evaluate the qualitative and quantitative toxic effects of this therapy. OUTLINE: Patients are described according to stage, performance status, prior radiotherapy, prior surgery, and prior mitotane therapy. Patients receive suramin IV for 5 days in the first week, then twice a week for 2 weeks, and then weekly for a total of 12 weeks. Hydrocortisone is taken PO twice daily. Following a 12 week rest, patients receive a second course; those with stable or responding disease continue treatment for a maximum of four courses. PROJECTED ACCRUAL: A maximum of 40 patients will be accrued at a rate of 6-7 per year.

Conditions

• Adrenocortical Carcinoma

Interventions

Type	Name	Description
DRUG	suramin
DRUG	therapeutic hydrocortisone

Timeline

• Start date: 1997-03-01
• Primary completion: 2004-01-01
• Completion: 2004-01-01
• First posted: 2004-07-30
• Last updated: 2012-10-05

Locations

65 sites across 1 country: United States